--- title: "LogicBio Therapeutics (LOGC) to Release Earnings on Wednesday" type: "News" locale: "en" url: "https://longbridge.com/en/news/285382406.md" description: "LogicBio Therapeutics (OTCMKTS:LOGC) is set to release its Q1 2026 earnings on May 13, with analysts predicting a loss of ($0.0409) per share. The company's stock opened at $8.60, with a market cap of $392.76 million. Goldman Sachs recently increased its holdings in LogicBio by 284.9%, owning 2.00% of the company. However, Wall Street Zen downgraded the stock from \"hold\" to \"sell\". LogicBio focuses on genetic medicine, developing gene therapy treatments using its GeneRide and sAAVy platforms." datetime: "2026-05-06T12:55:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285382406.md) - [en](https://longbridge.com/en/news/285382406.md) - [zh-HK](https://longbridge.com/zh-HK/news/285382406.md) --- # LogicBio Therapeutics (LOGC) to Release Earnings on Wednesday LogicBio Therapeutics (OTCMKTS:LOGC - Get Free Report) will likely be issuing its Q1 2026 resultson Wednesday, May 13th. Analysts expect LogicBio Therapeutics to post earnings of ($0.0409) per share for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 5:00 PM ET. Get **LogicBio Therapeutics** alerts: ## LogicBio Therapeutics Trading Down 0.1% LOGC stock opened at $8.60 on Wednesday. LogicBio Therapeutics has a 12-month low of $6.40 and a 12-month high of $9.14. The stock has a market cap of $392.76 million, a price-to-earnings ratio of -7.89 and a beta of 2.10. The business's 50-day moving average is $8.24 and its 200 day moving average is $7.89. ## Institutional Inflows and Outflows An institutional investor recently raised its position in LogicBio Therapeutics stock. Goldman Sachs Group Inc. boosted its holdings in shares of LogicBio Therapeutics, Inc. (OTCMKTS:LOGC - Free Report) by 284.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 526,673 shares of the company's stock after acquiring an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned about 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 46.05% of the company's stock. ## Wall Street Analysts Forecast Growth Separately, Wall Street Zen lowered LogicBio Therapeutics from a "hold" rating to a "sell" rating in a research note on Sunday, March 29th. **Get Our Latest Analysis on LogicBio Therapeutics** ## LogicBio Therapeutics Company Profile (Get Free Report) LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. ## Read More - Five stocks we like better than LogicBio Therapeutics _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in LogicBio Therapeutics Right Now? Before you consider LogicBio Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LogicBio Therapeutics wasn't on the list. While LogicBio Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [LOGC.US](https://longbridge.com/en/quote/LOGC.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [LOGCD.US](https://longbridge.com/en/quote/LOGCD.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) ## Related News & Research - [23andMe data breach victims deserve $46.75 million payout, bankruptcy administrator says](https://longbridge.com/en/news/289517783.md) - [New Talvey Plus Darzalex Faspro Data Demonstrate The Strength Of A Bispecific Combination In Earlier-Line Relapsed Or Refractory Multiple Myeloma](https://longbridge.com/en/news/289663072.md) - [NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma](https://longbridge.com/en/news/289441609.md) - [Anocca doses first patients with precision TCR‑T therapy](https://longbridge.com/en/news/289439697.md) - [Does Zevra Therapeutics (ZVRA) Patent Push and Board Structure Signal a Shifting Risk Profile?](https://longbridge.com/en/news/289197310.md)